

Special Issue

Drug Design and Discovery for Treatment of Coronavirus Disease (COVID-19)

Message from the Guest Editor

This Special Issue is related to the ongoing Covid-19 pandemic and will focus on the current advances and challenges in discovering and developing effective drugs targeting severe acute respiratory syndrome coronavirus (SARS-CoV)-2. While many advances have been made in developing vaccines, there is still a critical need for developing effective antiviral therapies. Avenues for developing SARS-CoV-2 therapies could include inhibitors that target essential viral proteins, high throughput screening campaigns targeting viral replication, novel therapies regulating the host immune system, or the repurposing of existing drugs among many other approaches. Such endeavors and discoveries will complement ongoing vaccination rollouts and will remain at the forefront as we combat this global pandemic. All researchers working in the fields of drug discovery and improvement, viral inhibition, and pre-clinical studies with novel therapies are cordially invited to contribute original research papers or reviews to this Special Issue of *Molecules*, which report on efforts towards targeting SARS-CoV-2.

Guest Editor

Dr. Ross Larue

Division of Pharmaceutics and Pharmacology, The Ohio State University, Columbus, OH 43210, USA

Deadline for manuscript submissions

closed (31 March 2022)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/76368

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 30th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarInLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2025).